Expansion of Hematology Services to Include Oncology
Spherix Global Insights, a leading independent market intelligence and advisory firm, is proud to announce its recent expansion into the oncology sector. As of the fourth quarter of 2025, the firm will integrate select oncology indications into its existing hematology franchise. This new initiative is expected to cover multiple myeloma and will also include additional focus on myelodysplastic syndrome and various B-cell malignancies starting in 2026.
Reasons Behind the Expansion
The therapeutic areas chosen for this expansion reflect the rapidly changing landscape of biopharmaceutical innovation and their increasing importance in the broader hematology and oncology markets. With both established therapies and a promising pipeline of emerging treatments, this new focus will provide clients with essential market insights, strategic advisory sessions, and specialized services tailored to the unique challenges posed by these therapeutic areas.
Comprehensive Market Insights
At the heart of the Hematology/Oncology Franchise is robust foundational research that benchmarks physician attitudes, prescribing trends, and market dynamics. By building on this data over the next year, Spherix will offer an extensive series of publications that detail changes in clinical practices, emerging treatments, and competitive movements across key oncology indications.
Service Offerings for the Inaugural Year
This newly expanded franchise plans to introduce various comprehensive service offerings in its first year, including:
Multiple Myeloma Insights
- RealTime Dynamix™: Multiple Myeloma, US
- Patient Chart Dynamix™: Multiple Myeloma, US
- Patient Voice Dynamix™: Multiple Myeloma, US
- Market Dynamix™: Multiple Myeloma, EU
Focus on Myelodysplastic Syndrome
- Market Dynamix™: Myelodysplastic Syndrome
B-Cell Malignancies Coverage
- RealTime Dynamix™: Large B-Cell Lymphoma, US
- Patient Chart Dynamix™: Large B-Cell Lymphoma, US
- Patient Chart Dynamix™: Chronic Lymphocytic Leukemia, US
- Market Dynamix™: Large B-Cell Lymphoma, US
- Market Dynamix™: Chronic Lymphocytic Leukemia, US
- Patient Voice Dynamix™: B-Cell Malignancies, US
Spherix's Commitment to the Biopharmaceutical Market
By pairing clinical realities with commercial strategies, Spherix Global Insights remains a vital partner for biopharmaceutical companies seeking to navigate the ever-changing market landscape. With their independence and expertise, they provide actionable intelligence that empowers clients to make informed decisions throughout the product lifecycle.
The Broader Impact of the Expansion
As they continue to build upon their hematology franchise, Spherix Global Insights is dedicated to delivering unparalleled market insights and advisory services. This expansion aligns with ongoing trends and requires an astute understanding of the rapid advancements in treatments for diseases like multiple myeloma, myelodysplastic syndrome, and B-cell malignancies.
Insights From Leadership
According to Sarah Hendry, the Hematology/Oncology Franchise Head, "Expanding our hematology franchise to include oncology represents a strategic step forward that directly aligns with our clients’ needs. The pace of therapeutic advancement in these areas is remarkable, and we are committed to equipping our partners with the timely intelligence they need to excel."
Frequently Asked Questions
What new areas is Spherix Global Insights expanding into?
Spherix Global Insights is expanding its hematology franchise to include select oncology indications.
What specific conditions will be covered under the new franchise?
The new franchise will cover multiple myeloma, myelodysplastic syndrome, and B-cell malignancies.
What type of services will be offered in the inaugural year?
They will offer services such as RealTime Dynamix™, Patient Chart Dynamix™, and Market Dynamix™ for various cancers.
How does Spherix ensure the accuracy of its insights?
Spherix utilizes independent primary research and deep therapeutic expertise to deliver reliable market intelligence.
Who will benefit from Spherix's expanded services?
Biopharmaceutical companies seeking market insights and strategic guidance will benefit from these enhancements.
